stars 1 stars 2 stars 3

We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS LOHMANN Therapie-Systeme AG. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches (“MAP”) for the transdermal delivery of large molecule, biological actives. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.

Website https://www.ltslohmann.com/en/
Revenue $371.3 million
Employees 107 (62 on RocketReach)
Founded 2023
Industry Pharmaceutical Manufacturing

LTS Device Technologies Questions

The LTS Device Technologies annual revenue was $371.3 million in 2026.

Douglas Stout is the Vice President of New Business Development of LTS Device Technologies.

62 people are employed at LTS Device Technologies.

Top LTS Device Technologies Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users